Asset
MIZAGLIFLOZIN
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05721729 | phase2 | completed | 2023-06-23 | 2024-05-01 | Vogenx, Inc. | Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions |
| NCT07760961 | phase2 | not_yet_recruiting | 2026-10-01 | 2027-10-01 | Vogenx, Inc. | Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia |
| NCT05541939 | phase2 | completed | 2022-09-13 | 2023-02-17 | Vogenx, Inc. | Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects |
FDA applications (0)
This company has no applications containing this asset.